Journal: Drug Invention Today

Article Id: JPRS-D(DD)-00003019
Title: Cost-effectiveness analysis of aripiprazole-escitalopram with aripiprazole-agomelatine as bipolar treatment in a pharmacy in Bandung, Indonesia
Category: Drug (Discovery/Development)
Section: Research Article
  • Abstract
  • Audio Abstract
  • Authors
  • Pdf File
  • Citation
  • My Reference
  • Methodology
  • Abstract

    Background: According to WHO in 2016, there are 60 million people affected by bipolar, this case continues to increase, including in Indonesia. The prevalence of bipolar disorder varies between 1-4 percent in Indonesia. At a pharmacy located in the city of Bandung, where a psychiatrist practices, this case ranks first in a variety of other mental disorders, namely 34.1% (in 2016). Aim: The aim of the study was to analyze more cost-effective therapy between the combination of aripiprazole and escitalopram with aripiprazole and agomelatine in a pharmacy in Bandung, Indonesia. Method: The outcome used was (Montgomery Asberg Depression Rating Scale/MADRS reduction) while the cost component used is direct cost. This study was conducted retrospectively in the January-December 2016 of 90 continuous phase bipolar disorder patients in a pharmacy in Bandung, using the perspective of patients and pharmacies, with direct cost components. The intention of the patient perspective means the patient cost component, and the intention of pharmacy perspective meant the pharmacy cost component. The pharmacoeconomic method was Cost Effectiveness Analysis. Data was obtained from medical records and financial division. Results: From the statistical tests performed on the outcome group, the p-value obtained was 0.293. Based on Average Cost Effectiveness Ratio (ACER), aripiprazole and escitalopram was more cost-effective than aripiprazole and agomelatine (IDR 1,057,705/MADRS score from patients perspective and IDR 842,705/MADRS scores from institutional perspective). Then Incremental Cost Effectiveness Ratio (ICER) was IDR 470,000/MADRS score from patients perspective and IDR 265,499 from pharmacy perspective. Conclusion: It indicated that aripiprazole and agomelatine is more cost effective than of aripiprazole and escitalopram in two perspective because there was a decrease in costs/MADRS score.

  • Abstract Audio

    No Audio file found

  • About the authors and Affiliations

    Author(s) Name:

    Yulia Wardati*, Desi Kristian Indrawati

    Affiliation(s) Name:

    Department of Pharmacy, Universitas Al-Ghifari, Bandung, West Java, Indonesia


    *Corresponding author: Yulia Wardati, Department of Pharmacy, Universitas Al-Ghifari, Bandung, West Java, Indonesia.

  • View Article File in pdf format.

    Article File
  • View Article Citation Here.

    0 View More
  • How to Cite my Article.

    Author:

    Yulia Wardati*, Desi Kristian Indrawati

    Title:Cost-effectiveness analysis of aripiprazole-escitalopram with aripiprazole-agomelatine as bipolar treatment in a pharmacy in Bandung, Indonesia
    Journal:Drug Invention Today
    Vol(issue):10 (December [ Special Issue 5 ])
    Year:2018
    Page No: (3776-3780)
  • Experimental Methods Keywords

    Methodology:Bipolar, Cost-effectiveness analysis,
    Research Materials: Agomelatine, Aripiprazole,Escitalopram

Keywords

Agomelatine Aripiprazole Bipolar Cost-effectiveness analysis Escitalopram

Our Services

Most Downloaded List